- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05750628
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria (PLATINUM)
A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Azaguie, Côte D'Ivoire, BP 173
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Navrango, Ghana, VWJ6+8WF
- Recruiting
- Novartis Investigative Site
-
-
-
-
Central Kenya
-
Kisumu, Central Kenya, Kenya, 3433-40100
- Recruiting
- Novartis Investigative Site
-
-
Kisumu
-
Ahero, Kisumu, Kenya, 40100
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Kampala, Uganda
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients ≥18 years of age for Part A and ≥12 years of age for Part B at screening.
- Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 5,000 to 150,000 asexual parasite count/μl of blood for P. falciparum for Part A and between 1,000 to 150,000 asexual parasite count/μl of blood for Part B
- Patients in Part A must weigh between 40 kg and 90 kg. Patients in Part B must weigh between 35 kg and 90 kg at screening.
Exclusion Criteria:
- Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
- Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:
- AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin
- AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN
- Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
- Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening.
- Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception.
History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:
- Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker
- History of familial long QT syndrome or known family history of Torsades de Pointe.
- Resting heart rate (physical exam or 12 lead ECG) < 60 bpm
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A1: Dose Level 1 INE963
|
oral INE963
|
Experimental: Cohort A1: Dose Level 2 INE963
|
oral INE963
|
Experimental: Cohort A1: Dose Level 3 INE963
|
oral INE963
|
Experimental: Cohort B1: KAE609 + INE963
|
oral INE963
oral KAE609 (Cipargamin)
|
Active Comparator: Cohort B1: SoC (Coartem)
|
SoC (Coartem)
|
Experimental: Cohort B2: KAE609 + KLU156
|
oral sachet KLU156 (KAF156 + lumefantrine)
oral KAE609 (Cipargamin)
|
Active Comparator: Cohort B2: SoC (Coartem)
|
SoC (Coartem)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: parasite clearance time (PCT)
Time Frame: up to Day 7
|
Part A: To assess the parasite clearance time (PCT) of oral doses of an anti-malarial agent administered as monotherapy in patients with uncomplicated P. falciparum malaria.
PCT is defined as the time from the first positive blood slide at inclusion to the time of the first negative slide followed by two consecutive slides.
|
up to Day 7
|
Part B: polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)
Time Frame: Day 29
|
Part B: To assess the 28-day cure rate of an anti malarial agent administered orally as combination therapy versus the standard of care (SoC) in patients with uncomplicated P. falciparum malaria.
ACPR is defined as the absence of parasitemia on Study Day 29 irrespective of axillary temperature, without previously meeting any of the criteria of Early Treatment Failure (ETF) or Late Clinical Failure (LCF) or Late Parasitological Failure (LPF).
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: PCR-corrected and uncorrected ACPR
Time Frame: Day 29
|
Part A: To assess the 28-day cure rate of an anti malarial agent administered orally as monotherapy in patients with uncomplicated P. falciparum malaria
|
Day 29
|
Part B: PCT
Time Frame: up to Day 7
|
Part B: To assess the parasite clearance time (PCT) of oral combinations of anti malarial agents versus the standard of care (SoC) in patients with uncomplicated P. falciparum malaria
|
up to Day 7
|
Part B: PCR-uncorrected ACPR
Time Frame: Day 29
|
Part B: To assess the 28-day cure rate of an anti malarial agent administered orally as combination therapy versus the SoC in patients with uncomplicated P. falciparum malaria
|
Day 29
|
Area under the concentration-time curve from time zero to the last measurable concentration sampling time (AUClast) of the anti-malarial agents
Time Frame: Day 22
|
To characterize the pharmacokinetics (PK) of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
AUClast is the area under the curve (AUC) from time zero to the last measurable concentration sample time (tlast)
|
Day 22
|
Area under the concentration-time curve from time zero to infinity (AUCinf) of the anti-malarial agents
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
AUCinf is the AUC from time zero to infinity.
|
Day 22
|
Maximum observed concentration (Cmax) of the anti-malarial agents
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
Cmax is the maximum (peak) observed plasma, blood, serum, or other blood fluid drug concentration after single dose administration.
|
Day 22
|
Time to reach maximum observed concentration (Tmax)
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration.
|
Day 22
|
Elimination half-life (T1/2) of the anti-malarial agents
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
T1/2 is the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve.
|
Day 22
|
Total body clearance (CL/F) of the anti-malarial agents
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
Cl/F is the total body clearance of drug from the plasma.
|
Day 22
|
Apparent volume of distribution (Vz/F) of the anti-malarial agents
Time Frame: Day 22
|
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria.
Vz/F is the apparent volume of distribution during terminal phase.
|
Day 22
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 43
|
Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs), and laboratory results qualifying and reported as AEs.
|
Day 43
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CADPT13A12201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Plasmodium Falciparum Malaria
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati...CompletedUncomplicated Plasmodium FalciparumIndonesia
-
University of OxfordNot yet recruitingUncomplicated Plasmodium Falciparum Malaria
-
Ministry of Public Health, Democratic Republic...Centers for Disease Control and Prevention; Global FundActive, not recruitingUncomplicated Plasmodium Falciparum MalariaCongo, The Democratic Republic of the
-
Medicines for Malaria VentureShin Poong Pharmaceuticals; Institute of Tropical Medicine, University of TuebingenCompletedPyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum MalariaUncomplicated Plasmodium Falciparum MalariaGabon
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research CouncilNot yet recruitingUncomplicated Plasmodium Falciparum MalariaTanzania
-
Novartis PharmaceuticalsEuropean and Developing Countries Clinical Trials Partnership (EDCTP)RecruitingUncomplicated Plasmodium Falciparum MalariaBurkina Faso, Mali, Gabon
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian Armed Forces and other collaboratorsSuspendedUncomplicated Plasmodium Falciparum MalariaCambodia
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia